To switch or not to switch: implications of sequencing adjuvant endocrine therapy in patients with breast cancer
Giuseppe Curigliano and Aron Goldhirsch*
Correspondence *Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
Email aron.goldhirsch@ibcsg.org
This article has no abstract so we have provided the first paragraph of the full text.
Adjuvant treatments for breast cancer have significantly improved disease-free survival and reduced mortality in postmenopausal women. The recognition that endocrine agents might represent the best treatment for patients with endocrine-responsive breast cancer was a paradigm shift. Subsequently, in upfront comparisons of more than 10,000 women included in randomized trials, the AIs anastrozole and letrozole were shown to be more effective than tamoxifen, when adjuvant treatment was administered for 5 years in each case.1, 2 Compared with no further adjuvant therapy, the addition of 5 years' adjuvant letrozole increased disease-free survival in postmenopausal women with endocrine-responsive disease who had already completed 5 years' treatment with adjuvant tamoxifen.3
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.